The ONE-P ('Organic nano-materials for electronics and photonics: design, synthesis, characterisation, processing, fabrication and applications') project has been allocated EUR 18 million under the 'Nanosciences, nanotechnologies, materials and new production technologies' (NMP) Theme of the Seventh Framework Programme (FP7). The project counts 28 partners from 10 EU Member States. The ONE-P project will work in the fast-growing world of organic, carbon-based semiconductors.
PRINS is the Research Infrastructure arm of a broader initiative, the ENIAC European Technology Platform. PRINS will bridge the area between research and market-driven applications and provide Europe with the ability to master the revolutionary transition from Microelectronics to Nanoelectronics, i.e. down to the level of individual atoms.
The PHANTOMS Foundation is a non-profit organisation, whose mission is to provide a platform of services and information for researchers active in Nanotechnology and Emerging Nanoelectronics in particular. This mission is accomplished by establishing a network of researchers that exchange experience and their latest results through several channels such as workshops, newsletters, WEB site, etc
Phonasum is a network of researchers and practitioners working in the field of photocatalysis from all around Europe. The main objective is to increase via a concerted European effort the fundamental knowledge of nanocrystalline photoactive materials and development of new products, which utilize self sterilizing and self cleaning photoactive materials in specific industrially relevant application fields such as self-cleaning and anti-microbial surfaces, water treatment, air purification and general hygienic applications.
PHOREMOST is the result of a decision to establish a Network of Excellence in the area of Nanophotonics and Molecular Photonics to address the near- and long term needs of photonic functional components.
PneumoNP is a collaborative research program aiming at the development of a nanotheragnostic system for the treatment of Gram-negative bacterial infections of the lung, with focus on Klebsiella pneumoniae caused infections.